METHOD - Phase I/II Study of Intramyocardial Injection of Bone Marrow Derived Mononuclear Cells in Chronic Ischemic Disease
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Troponin samples
研究概览
简要总结
Intramyocardial, NOGA guided injection of bone marrow derived mononuclear cells in patients with chronic ischemic heart disease and LVEF < 40%. The primary objective is to determine whether the administration of the cells improves recovery of the left ventricular function. Secondary objective is the finding of clinical or paraclinical parameters to predict potential benefits of the treatment (basing on MRI characteristics such as size, transmurality of the myocardial infarction and peri-lesional ischemia).
In the first part of the study 10 patients are treated without control group. This phase serves as feasibility and safety part of the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Chronic cardiac ischemic disease at least 4 months after one ore more myocardial infarctions in a stable phase of the disease without option for revascularization
- •LVEF at echocardiography ≤ 40%
- •Significant regional LV wall motion dysfunction in the infarct related territory
- •Symptoms NYHA II-IV or CCS II-III (at least class III according to one of the two classifications)
- •Patient agrees to comply with all follow-up evaluations
- •Age > 18 years old
- •Patient has been informed of the nature of the clinical trial and agrees to its provision and has provided written informed consent
排除标准
- •Abnormal regional wall motion outside the infarct region
- •Need for revascularization in a non infarct-related coronary within 6 months
- •Patient has moderate to severe aortic valve disease, aortic or mitral prosthetic valve
- •Patient has a significant mitral valve insufficiency (Effective Regurgitant office - ERO - > 0.2 cm2 with possibility of mitral valve surgery
- •Left ventricular thrombus at echocardiography
- •LV-aneurysma planned surgical aneurysmectomy
- •LV-wall thickness < 5mm in the target territory
- •Congenital heart disorder of hemodynamic relevance
- •Known active infection or chronic infection with HIV, HBV or HCV
- •Chronic inflammatory disease
- •Serious concomitant disease with a life expectancy of less than one year
- •Follow up impossible (no fixed abode, etc)
- •Contraindication for cardiac MRI (i.e. pace maker, neurostimulator, claustrophobia)
- •Severe renal failure (creatinine > 250 mmol/l)
- •Relevant liver disease (GOT > 2x norm or spontaneous INR > 1,5)
- •Anemia (Hb < 8.5 mg/dl), Thrombocytopenia (< 100.000/µl)
- •Women of child bearing potential or pregnancy
- •Participation at a clinical trial in the last 30 days
研究组 & 干预措施
Intramyocardial injection of BM cells
干预措施: intramyocardial injection of BM cells (Other)
Intramyocardial / intracoronary injection of BM cells
干预措施: intramyocardial / intracoronary injection of BM cells (Other)
control
干预措施: Best medical therapy (Other)
结局指标
主要结局
Troponin samples
时间窗: 1 day after cell injection
Measurements of Troponine after cell injection
Number of patients with adverse events at mid/long term
时间窗: up to 12 months after cell injection
Number of patients with adverse events at short term
时间窗: within 1 week after cell injection
次要结局
- change in LVEF(6 months vs. baseline)
- change in Quality of life(6 months vs. baseline)
- change in Vo2 max(6 months vs. bl)
研究者
Daniel Suerder
MD; senior attendant of Cardiology
Cardiocentro Ticino